Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberculosis
Conditions
Tuberculosis
Trial Timeline
Jan 1, 2007 → Feb 1, 2008
NCT ID
NCT00440544About Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1
Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 is a phase 1 stage product being developed by Novartis for Tuberculosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00440544. Target conditions include Tuberculosis.
What happened to similar drugs?
3 of 5 similar drugs in Tuberculosis were approved
Approved (3) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00440544 | Phase 1 | Terminated |
Competing Products
20 competing products in Tuberculosis